Synthesis, Conjugation, and Radiolabeling of a Novel Bifunctional Chelating Agent for 225Ac Radioimmunotherapy Applications
Citations Over TimeTop 10% of 2000 papers
Abstract
225Ac (t(1/2) = 10 days) is an alternative alpha-emitter that has been proposed for radioimmunotherapy (RIT) due to its many favorable properties, such as half-life and mode of decay. The factor limiting use of (225)Ac in RIT is the lack of an acceptably stable chelate for in vivo applications. Herein is described the first reported bifunctional chelate for (225)Ac that has been evaluated for stability for in vivo applications. The detailed synthesis of a bifunctional chelating agent 2-(4-isothiocyanatobenzyl)-1,4,7,10,13, 16-hexaazacyclohexadecane- 1,4,7,10,13,16-hexaacetic acid (HEHA-NCS) is reported. This ligand was conjugated to three monoclonal antibodies, CC49, T101, and BL-3 with chelate-to-protein ratios between 1.4 and 2. The three conjugates were radiolabeled with (225)Ac, and serum stability study of the [(225)Ac]BL-3-HEHA conjugate was performed.
Related Papers
- → Clinical radioimmunotherapy—the role of radiobiology(2011)237 cited
- → Concepts in radioimmunotherapy and immunotherapy: Radioimmunotherapy from a Lym-1 perspective(2005)24 cited
- → Response to Radioimmunotherapy Correlates with TumorpO2Measured by EPR Oximetry in Human Tumor Xenografts(2001)38 cited
- Advances in monoclonal antibodies for radioimmunotherapy(2002)
- → Correction: Effects of the support on bifunctional one-step synthesis of methylal via methanol oxidation catalysed by Fe–Mo-based bifunctional catalysts(2022)